This Pharma stock, which deals in the business of manufacture, distribution, and marketing of products related to pharmaceuticals, was up 3 percent after permission to sell Durvalumab in India used for the treatment of Lung Cancer.
Share Price Movement
In Monday’s trading session, AstraZeneca Pharma India‘s share price touched a day’s high of Rs. 7,679.85, which is 2.75 percent higher. The share price reiterated from the day’s high and was trading at Rs. 7,578.40, which is 1.40 percent higher than the previous closing price of Rs. 7,474 apiece. In the past year, the stock has given around 41 percent returns and outperformed the Nifty Index.
What Happened
The company’s stock was in focus after AstraZeneca Pharma India exchange filing revealed that they have received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab solution for the infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) for an additional indication.
This Durvalumab is indicated for the treatment of patients with limited stage small cell lung cancer (LS-SCLC) whose disease has not progressed following the platinum-based chemoradiation therapy (CRT). This permission helps the company to market this solution in India, subject to the receipt of related statutory approvals if required.
Financials
In its latest filing for the quarter ending December 2024, the company reported a 43.79 percent rise in revenue, reaching Rs. 440 crore compared to Rs. 306 crore in Q3FY24. During the same period, net profit increased by 93.75 percent to Rs. 31 crore in Q3FY25, compared to Rs. 16 crore in Q3FY24.
Business segment
AstraZeneca recognises its operating revenue under the Healthcare segment as its sole segment as of the December 2024 quarter.
Company Overview
AstraZeneca Pharma India Limited (AZPIL), established in 1979, is a subsidiary of AstraZeneca Plc, UK. It operates in therapeutic areas like cardio-metabolism, oncology, and respiratory diseases, with manufacturing and headquarters in Bengaluru, Karnataka.
Written by – Santhosh S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
